Free Trial

Viatris (VTRS) Stock Forecast & Price Target

$11.44
-0.04 (-0.35%)
(As of 10/25/2024 ET)

Viatris - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Viatris in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a buy rating for VTRS.

Consensus Price Target

$14.00
22.38% Upside
According to the 2 analysts' twelve-month price targets for Viatris, the average price target is $14.00. The highest price target for VTRS is $15.00, while the lowest price target for VTRS is $13.00. The average price target represents a forecasted upside of 22.38% from the current price of $11.44.
Get the Latest News and Ratings for VTRS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viatris and its competitors.

Sign Up

VTRS Analyst Ratings Over Time

TypeCurrent Forecast
10/28/23 to 10/27/24
1 Month Ago
9/28/23 to 9/27/24
3 Months Ago
7/30/23 to 7/29/24
1 Year Ago
10/28/22 to 10/28/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$14.00$14.00$14.00$14.00
Forecasted Upside22.38% Upside22.38% Upside22.38% Upside22.38% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

VTRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VTRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viatris Stock vs. The Competition

TypeViatrisMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside22.38% Upside7,918.34% Upside9.13% Upside
News Sentiment Rating
Positive News

See Recent VTRS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/19/2024Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$15.00+27.44%
3/28/2024Piper Sandler
2 of 5 stars
 Reiterated RatingNeutral ➝ Neutral$11.00 ➝ $13.00+9.80%
10/23/2023Bank of America
4 of 5 stars
 DowngradeNeutral ➝ Underperform$13.00 ➝ $9.00-3.23%
6/23/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$11.00+9.45%
2/17/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$16.00 ➝ $14.00+20.17%
11/15/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$13.00 ➝ $14.00+21.00%
11/9/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral$9.00 ➝ $12.00+10.80%
11/7/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:24 AM ET.


VTRS Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Viatris is $14.00, with a high forecast of $15.00 and a low forecast of $13.00.

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viatris in the last year. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VTRS shares.

According to analysts, Viatris's stock has a predicted upside of 22.38% based on their 12-month stock forecasts.

Analysts like Viatris less than other "medical" companies. The consensus rating score for Viatris is 2.50 while the average consensus rating score for "medical" companies is 2.79. Learn more on how VTRS compares to other companies.


This page (NASDAQ:VTRS) was last updated on 10/27/2024 by MarketBeat.com Staff
From Our Partners